{"analyses":[{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.23","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.84"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8"},{"groupId":"OG001","value":"95.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2884"},{"groupId":"OG001","value":"2877"}],"units":"Participants"}],"description":"Compare locoregional recurrence-free survival (LRRFS). LRRFS is defined as the time from randomization to the date of the first event: local/regional invasive ipsilateral recurrence, contralateral invasive breast cancer, or death from any cause. Patients with second primary invasive cancers of non-breast origin or distant recurrence will be censored at the date of diagnosis. Surviving patients who are event-free will be censored at: the date of last disease assessment, or withdrawal of consent to be followed, whichever occurs first.","groups":[{"description":"Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.","id":"OG000","title":"Palbociclib Plus Endocrine Therapy (Arm A)"},{"description":"Standard adjuvant endocrine therapy for a duration of at least 5 years.","id":"OG001","title":"Endocrine Therapy Alone (Arm B)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4 years","title":"Locoregional Recurrences-free Survival (LRRFS)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}